CONVERGENCE PHARMACEUTICALS
Convergence Pharmaceuticals is an independent biotechnology company focused on the development of novel analgesics with potentially commercially attractive efficacy, responder-rate and side effect profiles. The Company was formed in October 2010 following the acquisition of certain neuroscience clinical assets from GlaxoSmithKline (รขโฌลGSKรขโฌย). Convergence Pharmaceuticals has a pipeline of differentiated clinical-stage compounds targeting the points of convergence in chronic pain signaling through modulation of specific ion-channels.
CONVERGENCE PHARMACEUTICALS
Industry:
Biotechnology Health Care Medical Neuroscience
Founded:
2010-01-01
Address:
Cambridge, Cambridgeshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.convergencepharma.com
Total Employee:
11+
Status:
Closed
Contact:
44 1223 755 501
Email Addresses:
[email protected]
Total Funding:
35.4 M USD
Technology used in webpage:
SPF Amazon AWS Global Accelerator
Current Advisors List
Current Employees Featured
Founder
Investors List
New Leaf Venture Partners
New Leaf Venture Partners investment in Series A - Convergence Pharmaceuticals
SV Health Investors
SV Health Investors investment in Series A - Convergence Pharmaceuticals
Apposite Capital
Apposite Capital investment in Series A - Convergence Pharmaceuticals
Official Site Inspections
http://www.convergencepharma.com
- Host name: a904c694c05102f30.awsglobalaccelerator.com
- IP address: 13.248.169.48
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "Convergence Pharmaceuticals"
Convergence Pharmaceuticals - Crunchbase Company โฆ
Contact Email [email protected] Phone Number 44 1223 755 501 Convergence Pharmaceuticals is an independent biotechnology company โฆSee details»
Convergence Pharmaceuticals Ltd. Overview - SignalHire
Organization Website: convergencepharma.com : Convergence Pharmace... industries Pharma: Headquarters Location: Babraham Research Campus, Cambridge, CB22 3AT GB Babraham โฆSee details»
Convergence Pharmaceuticals Ltd.: Drug pipelines, Patents, Clinical ...
Jun 30, 2023 Explore Convergence Pharmaceuticals Ltd. with its drug pipeline, therapeutic area, technology platform, 4 clinical trials, 2 news, and 3 literature.See details»
Convergence Pharma - Company Profile - Tracxn
Convergence Pharma - Develops novel analgesics with better efficacy and less side effects.. Acquired by Biogen. Raised a total funding of $35.4M over 1 round from 4 investors. โฆSee details»
Convergence Pharmaceuticals - Cambridge, United Kingdom
Nov 22, 2011 convergencepharma.com +441223755501. Share. Xing Linkedin Facebook X E-mail Loading... Bookmark. Bookmark list; Bookmark. Convergence Pharmaceuticals. Maia โฆSee details»
Convergence Pharmaceuticals Ltd - Company Profile and News
Company profile page for Convergence Pharmaceuticals Ltd including stock price, company news, executives, board members, and contact informationSee details»
Convergence Pharmaceuticals Limited - Company Profile - Endole
Jan 6, 2015 Convergencepharma.com. See All Contacts . People. Officers. 3. Shareholders. 1. Controllers (PSC) 1. Kylie Michele Bromley. Director โข Australian โข Lives in UK โข Born in Mar โฆSee details»
Convergence Pharmaceuticals Ltd. - Business Information
View Convergence Pharmaceuticals Ltd. (www.convergencepharma.com) location in Berkshire, United Kingdom , revenue, industry and description. Find related and similar companies as โฆSee details»
Convergence Pharmaceuticals - PitchBook
When was Convergence Pharmaceuticals founded? Convergence Pharmaceuticals was founded in 2010. Where is Convergence Pharmaceuticals headquartered?See details»
CONVERGENCE PHARMACEUTICALS HOLDINGS LIMITED โฆ
CONVERGENCE PHARMACEUTICALS HOLDINGS LIMITED Company Profile | LONDON, United Kingdom | Competitors, Financials & Contacts - Dun & BradstreetSee details»
Orphanet: CONVERGENCE PHARMACEUTICALS LTD.
E-mail: [email protected]. Convergence Pharmaceuticals Ltd. Convergence Pharmaceuticals Ltd. Babraham Research Campus CAMBRIDGE CB22 3AT UNITED โฆSee details»
Convergence Pharmaceuticals Ltd. - ContactOut
Convergence Pharmaceuticals is focused on the development of novel analgesics with potentially commercially attractive efficacy, responder-rate and side effect profiles. The company was โฆSee details»
Convergence Pharmaceuticals - Products, Competitors, Financials ...
Headquarters Location. 90 High Holborn . London, England, WC1V 6XX, United Kingdom +44-(0)1223-755-501See details»
CONVERGENCE PHARMACEUTICALS LIMITED - Companies House
CONVERGENCE PHARMACEUTICALS LIMITED - Free company information from Companies House including registered office address, filing history, accounts, annual return, officers, โฆSee details»
CONVERGENCE PHARMACEUTICALS HOLDINGS LIMITED
CONVERGENCE PHARMACEUTICALS HOLDINGS LIMITED - Free company information from Companies House including registered office address, filing history, accounts, annual return, โฆSee details»
Convergence Pharmaceuticals Ltd Overview - Salary.com
Discover essential details about Convergence Pharmaceuticals Ltd, including address, contact, and journey of our company's evolution.See details»
Convergence Pharmaceuticals Ltd. (Convergence Pharmaceuticals โฆ
This was an international, multicenter, placebo-controlled, randomized withdrawal study that included a 7-day run-in period, a 21-day open-label phase, and a 28-day double-blind phase in โฆSee details»
Convergence Pharmaceuticals Ltd. Email and Phone | Salezshark
Name Designation Email Address Contact Number View Email & Phone; Joanne Palmer: Head of Clinical Operations ****@convergencepharma.com *****5329: View Email & Phone: Ged GiblinSee details»
Convergence Pharmaceuticals' Novel Sodium Channel Blocker
Jun 16, 2014 For more information about Convergence Pharmaceuticals, please contact: Convergence Pharmaceuticals Dr Clive Dix, Chief Executive Officer Brenda Reynolds, Chief โฆSee details»
Home - ConverGene
Developing First-in-Class Dual Inhibitors Targeting Both BET Bromodomains and Dopamine Receptor 2 for the Treatment of CancerSee details»